Apalutamide | List of Frontiers open access articles

Case Report

Published on 31 May 2022

Absence of PSA Flare With Apalutamide Administered 1 Hour in Advance With GnRH Agonists: Case Report

in Genitourinary Oncology

Zhiquan Hu
Zhenghao Liu
Zhiyuan Chen
Xing Zeng
Zhihua Wang
Chunguang Yang

Frontiers in Oncology

doi 10.3389/fonc.2022.878264

5,217 views
4 citations

Original Research

Published on 13 Feb 2025

Exploring skin adverse events and mechanisms of apalutamide using data mining algorithms and network pharmacology

in Pharmacology of Anti-Cancer Drugs

Yaqing Chen
Longzhuan Huang
Wenwei Li
Hangye Gu
Yong Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1517874

4,489 views
4 citations

Original Research

Published on 05 Jun 2023

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system

in Pharmacoepidemiology

Zhihong Fang
Zhiqiang Xu
Wei Zhu
Mingming Yu
Chunmei Ji

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1101861

6,938 views
24 citations

Case Report

Published on 11 Jan 2024

Case report: Apalutamide-induced severe lethal cutaneous adverse effects in China

in Cancer Immunity and Immunotherapy

Qi Wang
Huali Cao
Xuetong Zhang
Huifeng Wu
Zhuangli Tang

Frontiers in Immunology

doi 10.3389/fimmu.2023.1291564

4,194 views
12 citations

Systematic Review

Published on 31 Oct 2023

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer

in Cancer Endocrinology

Xiangyu Chen
Yang Pan
Qihua Wang
Congzhe Ren
Muwei Li
Xuexue Hao
Lijun Xie
Xiaoqiang Liu

Frontiers in Endocrinology

doi 10.3389/fendo.2023.1225033

5,200 views
4 citations

Original Research

Published on 19 May 2025

Liquid chromatography–tandem mass spectrometry assay for the simultaneous determination of apalutamide and its active metabolite N-desmethyl apalutamide, and its application in real-world patients with castration-resistant prostate cancer

in Drug Metabolism and Transport

Yuxuan Zhu
Lu Chen
Wenqiang Cheng
Dingyuan Yang
Lijuan Zhang
Jun Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1510583

2,529 views
1 citation

Brief Research Report

Published on 19 Oct 2023

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

in Pharmacology of Anti-Cancer Drugs

Yongbao Wei
Ruochen Zhang
Dewen Zhong
Zhensheng Chen
Gen Chen
Minggen Yang
Le Lin
Tao Li
Liefu Ye
Lili Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1284899

4,090 views
4 citations

Original Research

Published on 13 Oct 2025

Efficacy and safety of apalutamide, abiraterone acetate, and bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer

in Genitourinary Oncology

Jiabin Zhang
Qiang Wang
Junjie Zhou
Huiyu Gao
Peng Hao
Tao Wu

Frontiers in Oncology

doi 10.3389/fonc.2025.1656216

2,850 views

Original Research

Published on 06 Nov 2023

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial

in Cancer Molecular Targets and Therapeutics

Dingyuan Yang
Wenqiang Chen
Fei Lai
Mingxing Qiu
Jun Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1110807

2,868 views
1 citation

Systematic Review

Published on 10 Feb 2023

The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis

in Cancer Endocrinology

Xianlu Zhang
Gejun Zhang
Jianfeng Wang
Jianbin Bi

Frontiers in Endocrinology

doi 10.3389/fendo.2023.1131033

9,333 views
6 citations

Original Research

Published on 18 Apr 2024

Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world

in Genitourinary Oncology

Yutong Lu
Jingqi Jiang
Gaoyang Yang
Hui Ding
Qihui Zheng
Luhua Ji
Yuhan Wang
Zhilong Dong
Zhenxing Zhai
Junqiang Tian

Frontiers in Oncology

doi 10.3389/fonc.2024.1324181

6,124 views
5 citations

Original Research

Published on 20 Feb 2025

Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide

in Cancer Immunity and Immunotherapy

Qi Wang
Zhao-Ting Ren
Hui-Feng Wu
Hao-Chen Gu
Xia-Wei Li
Zhuang-Li Tang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1530919

2,564 views

Systematic Review

Published on 18 Sep 2020

Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis

in Genitourinary Oncology

Junru Chen
Yuchao Ni
Guangxi Sun
Banghua Liao
Xingming Zhang
Jinge Zhao
Sha Zhu
Zhipeng Wang
Pengfei Shen
Hao Zeng

Frontiers in Oncology

doi 10.3389/fonc.2020.519388

12,023 views
25 citations

Review

Published on 09 Mar 2023

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis

in Cancer Endocrinology

Xiangyu Chen
Qihua Wang
Yang Pan
Shangren Wang
Yuezheng Li
Hao Zhang
Mingming Xu
Hang Zhou
Xiaoqiang Liu

Frontiers in Endocrinology

doi 10.3389/fendo.2023.1134719

12,027 views
5 citations

Systematic Review

Published on 22 Sep 2025

A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer

in Genitourinary Oncology

Massimo Di Maio
Enrique Gonzalez-Billalabeitia
Laura Marandino
Pablo Maroto
Marc-Olivier Timsit
Irene Luccarini
Paul Robinson
Suzy Van Sanden
Boris A. Hadaschik

Frontiers in Oncology

doi 10.3389/fonc.2025.1468928

4,444 views

Brief Research Report

Published on 06 Oct 2025

A high eosinophil proportion increases the risk of skin-related adverse events induced by apalutamide in patients with prostate cancer

in Cancer Immunity and Immunotherapy

Yoshihiko Tasaki
Taku Naiki
Yoshihisa Mimura
Yosuke Sugiyama
Misato Tomita
Toshiharu Morikawa
Takashi Nagai
Rei Unno
Toshiki Etani
Shuzo Hamamoto

Frontiers in Immunology

doi 10.3389/fimmu.2025.1681734

1,758 views

Articles

Absence of PSA Flare With Apalutamide Administered 1 Hour in Advance With GnRH Agonists: Case Report

Exploring skin adverse events and mechanisms of apalutamide using data mining algorithms and network pharmacology

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system

Case report: Apalutamide-induced severe lethal cutaneous adverse effects in China

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer

Liquid chromatography–tandem mass spectrometry assay for the simultaneous determination of apalutamide and its active metabolite N-desmethyl apalutamide, and its application in real-world patients with castration-resistant prostate cancer

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

Efficacy and safety of apalutamide, abiraterone acetate, and bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial

The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis

Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world

Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide

Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis

A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer

A high eosinophil proportion increases the risk of skin-related adverse events induced by apalutamide in patients with prostate cancer